Investigators previously showed that Roux-en-Y gastric bypass (RYGB) was superior to sleeve gastrectomy for type 2 diabetes remission. In a recent secondary analysis of trial data, published in the Annals of Internal Medicine, both bariatric surgery approaches were highly effective for reducing nonalcoholic fatty liver disease.
Both procedures led to substantial reduction in hepatic steatosis at 5 weeks and an almost complete clearance of liver fat 1 year after surgery. All patients in the RYGB group and 94% in the sleeve gastrectomy group had no or low-grade steatosis.
Further research is warranted on long-term fibrosis progression or regression. The researchers will observe participants for an additional 5 years.